These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1363060)

  • 1. Disposition of human drug preparations in the horse. II. Orally administered fencamfamine.
    Delbeke FT; Debackere M
    J Pharm Biomed Anal; 1992 Sep; 10(9):651-6. PubMed ID: 1363060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion.
    Delbeke FT; Debackere M
    Biopharm Drug Dispos; 1981; 2(1):17-30. PubMed ID: 7236868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of human drug preparations in the horse. IV. Orally administered fenoprofen.
    Delbeke FT; Landuyt J; Debackere M
    J Pharm Biomed Anal; 1995 Jul; 13(8):1041-7. PubMed ID: 8580149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatography electrospray ionization tandem mass spectrometry for the detection of mesocarb abuse in horse doping.
    Appolonova SA; Baranov PA; Mesonzhnik NV; Brazhnikova DO; Rodchenkov GM
    Drug Test Anal; 2011 Oct; 3(10):717-23. PubMed ID: 21964865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of modafinil in human urine by gas chromatography-mass spectrometry.
    Tseng YL; Uralets V; Lin CT; Kuo FH
    J Pharm Biomed Anal; 2005 Oct; 39(5):1042-5. PubMed ID: 15993026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of hydroxylated mesocarb metabolites for doping control.
    Vahermo M; Suominen T; Leinonen A; Yli-Kauhaluoma J
    Arch Pharm (Weinheim); 2009 Apr; 342(4):201-9. PubMed ID: 19340833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of human drug preparations in the horse. I. Rectally administered indomethacin.
    Delbeke FT; Debackere M; Vynckier L
    J Vet Pharmacol Ther; 1991 Jun; 14(2):145-9. PubMed ID: 1920602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes.
    Hansson A; Knych H; Stanley S; Thevis M; Bondesson U; Hedeland M
    Drug Test Anal; 2015 Aug; 7(8):673-83. PubMed ID: 25560998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of xylazine and its metabolites by GC-MS in equine urine for doping analysis.
    Spyridaki MH; Lyris E; Georgoulakis I; Kouretas D; Konstantinidou M; Georgakopoulos CG
    J Pharm Biomed Anal; 2004 Apr; 35(1):107-16. PubMed ID: 15030885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated administration intensifies the reinforcing effect of fencamfamine in rats.
    DeLucia R; Planeta CS; Aizenstein ML; Scavone C
    Gen Pharmacol; 1997 Aug; 29(2):265-7. PubMed ID: 9251911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic studies of oxyguno in horses.
    Wong AS; Ho EN; Wan TS; Lam KK; Stewart BD
    Anal Chim Acta; 2015 Sep; 891():190-202. PubMed ID: 26388378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection, pharmacokinetics, and selected pharmacodynamic effects of methamphetamine following a single transmucosal and intravenous administration to exercised Thoroughbred horses.
    Knych HK; Arthur RM; Kanarr KL; McKemie DS; Kass PH
    Drug Test Anal; 2019 Sep; 11(9):1431-1443. PubMed ID: 31218824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of human drug preparations in the horse. V. Orally administered oxprenolol.
    Delbeke FT
    Biomed Chromatogr; 1996; 10(4):172-8. PubMed ID: 8831961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of food intake by fencamfamine in rats.
    DeLucia R; Planeta Cda S; Scavone C; Aizenstein ML
    Gen Pharmacol; 1987; 18(1):21-3. PubMed ID: 2881832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose.
    Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J
    J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection.
    Lho DS; Lee J; Kim S; Park J; Shin HS
    J Chromatogr B Biomed Appl; 1996 Dec; 687(1):253-9. PubMed ID: 9001971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The behavioral sensitization induced by fencamfamine is not related to plasma drug levels.
    Planeta CS; DeLucia R; Aizenstein ML
    Braz J Med Biol Res; 1995 Jun; 28(6):667-70. PubMed ID: 8547850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs in sport. The first 5 years of testing in South Africa.
    van der Merwe PJ; Hundt HK; Müller FO; van Velden DP
    S Afr Med J; 1988 Aug; 74(4):161-2. PubMed ID: 2900558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism which mediates the effects of long-term administration of fencamfamine in rats.
    Planeta CS; DeLucia R; Aizenstein ML; Scavone C
    Braz J Med Biol Res; 1989; 22(7):881-3. PubMed ID: 2576524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GC-MS and LC-(high-resolution)-MS(n) studies on the metabolic fate and detectability of camfetamine in rat urine.
    Welter J; Kavanagh P; Maurer HH
    Anal Bioanal Chem; 2014 Jun; 406(16):3815-29. PubMed ID: 24828975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.